ClinicalTrials.gg
CompletedNCT02773576Updated Feb 19, 2020Results posted

Safety and Tolerability of Risperidone Implants

A Phase 3 interventional study of Risperidone implant in Schizophrenia, sponsored by Braeburn Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-02-19.

Sponsored by Braeburn Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
48th of 123
140 · median 100
Started
2016
with 4 others
Phase 3
34 of 127
2 open now
Registered
103rd of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 48th largest by enrollment of the 123 interventional ones that give a count, is one of 5 that started in 2016, is one of 34 in phase 3, and was the 103rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia

Read the detailed description

The trial is to evaluate the 48-week safety and tolerability of risperidone implants as maintenance therapy in subjects with schizophrenia. This will be measured by the incidence of psychotic symptoms exacerbation/impending relapse, PANSS, CGI-I, CGI-S, adverse events, vital signs, clinical laboratory, physical exam and ECG findings, Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BARS), and Simpson-Angus Scale (SAS) and Investigator assessments.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has provided written .
  2. Male and female subjects 18 to 70 years of age, inclusive, at time of informed consent.
  3. Subjects with a current diagnosis of schizophrenia as defined by criteria and a history of the illness for at least 2 years prior to screening (as per subject, family, healthcare provider, and/or by previous medical records).
  4. Subject is assessed by the Investigator to be symptomatically stable with regard to his or her psychiatric condition at screening and baseline.
  5. Subject must be stable on their current antipsychotic medication for at least 30 days prior to screening.
  6. Subject has identified a caregiver or personal contact with whom the subject has significant contact with at least once per week.
  7. Subjects who have shown a previous response to antipsychotic treatment (other than clozapine) in the past year, according to the Investigator's opinion.
  8. Subjects who are currently being treated with one or two antipsychotics other than clozapine, and who, in the Investigator's judgment, require chronic treatment with an antipsychotic medication and would benefit from treatment with Risperidone Implants.
  9. Subjects who meet the following criteria:

    1. Outpatient status
    2. PANSS Total Score ≤ 80, and if PANSS score at baseline increases by ≥ 20% change from screening, the subject cannot participate in the study.
    3. PANSS scores of ≤ 4 on all of the following items:

      • Conceptual disorganization
      • Suspiciousness
      • Hallucinatory behavior
      • Unusual thought content
      • Hostility
    4. CGI-S ≤ 4 (moderately ill)
    5. Lack of suicidal ideation or behavior in Investigator's judgment
  10. Subjects who are able to understand the nature of the trial and follow protocol requirements, have the ability to read and understand the written word, and who can be reliably rated on assessment scales.
  11. Subjects who have completed adequate (5 half-lives unless otherwise specified) of prohibited concomitant medications, including mood stabilizers and strong inducers or inhibitors of CYP2D6 activity, prior to receiving oral risperidone or implant Risperidone.
  12. Subject has completed washout of 42 days for any fluoxetine containing compound.
  13. Female participants (if of and sexually active) and male participants (if sexually active with a partner of childbearing potential) who agree to use a medically acceptable and effective method throughout the study.
  14. Subject has a (BMI) ≥18.5 and ≤38.0 kg/m2.
  15. Subject is assessed by the Investigator to be symptomatically stable with regard to pre-existing medical conditions as evidenced by medical history, non-clinically significant findings on physical examination, vital signs, clinical laboratory evaluations (hematology, serum chemistries, and urinalysis) or 12-lead (ECG). Subjects may continue on their current prescribed medication regimens to control pre-existing medical and psychiatric conditions (other than schizophrenia) including the use of prescribed PRN medications.

Exclusion criteria

Exclusion Criteria:

  1. Known or allergy to lidocaine or any local anesthetic agent of the amide type (local anesthetic used during implant and explant procedures).
  2. Known sensitivity to polyurethane.
  3. Reports or reveals a presence of skin disorders (such as, but not limited to, skin cancer, psoriasis, eczema, or atopic dermatitis), and/or evidence of recent sunburn, scar tissue, tattoo, open sore, body piercing or branding at the intended implantation site that would interfere with the implantation procedure or interfere with implant site assessments as determined by the Investigator.
  4. History of abnormal scar formation or family history of keloid formation.
  5. Subjects with a current diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder are excluded.
  6. Subjects experiencing acute depressive symptoms within the past 30 days, according to the Investigator's opinion, that required treatment with an antidepressant.
  7. Subjects considered by the Investigator to be at imminent risk of suicide or injury to self, or subjects who within the past 6 months prior to Screening have attempted suicide, or who within the past 3 months prior to Screening have had active suicide ideation (positive answers to item 4 or 5 on the C-SSRS).
  8. Subjects with schizophrenia that are considered resistant/ to antipsychotic treatment by history.
  9. Subjects with a history of failure to clozapine treatment or response to clozapine treatment only.
  10. Subjects with a documented history of failure to respond to an adequate dose of risperidone or paliperidone treatment including long acting injectable formulations.
  11. Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on history or Investigator's judgment.
  12. Subjects who currently meet DSM-5 criteria for substance use disorder (moderate or severe); including alcohol and benzodiazepines, but excluding caffeine, nicotine, and marijuana.
  13. Females who are breast-feeding or will be breast feeding during the course of the study, and/or who have a positive serum pregnancy test result prior to receiving trial medication.
  14. Subjects with uncontrolled hypothyroidism or hyperthyroidism (unless condition has been stabilized with medications for at least the past 90 days).
  15. Subjects who have a clinically significant history or evidence of a medical condition that would expose them to an undue risk of a significant AE or interfere with assessments of safety or efficacy during the course of the trial.
  16. Subjects with epilepsy or a history of seizures, except for a single childhood febrile seizure, post traumatic, alcohol withdrawal, etc. A subject with a history of any seizure activity will have their case discussed with the medical monitor prior to subject's study enrollment.
  17. Subjects with a positive drug screen at screening for drugs of abuse without a prescription, excluding marijuana, will be discussed with the medical monitor.
  18. The following laboratory test, vital sign, and results are exclusionary:

    1. ≤ 75,000/mm3
    2. ≤ 9 g/dL
    3. Neutrophils, absolute ≤ 1000/mm3
    4. > 3x
    5. Alanine aminotransferase > 3x upper limit of normal
    6. Creatinine ≥ 2 mg/dL
    7. Diastolic blood pressure > 105 mmHg
    8. > 470 msec for females and QTc > 450 msec for males using the QTcF (Fridericia) correction
  19. Subject is positive.
  20. Active hepatitis. Subjects with no viral load, no acute inflammation and no clinical necessity for therapy will be allowed, at the discretion of the Investigator.
  21. Subjects with a history of an allergic hypersensitivity to antipsychotic agents.
  22. Subjects with a history of significant intolerance or who are refractory to antipsychotic agents.
  23. Subjects with a history of neuroleptic malignant syndrome.
  24. Subjects with clinically significant tardive dyskinesia at screening [any one AIMS item (1-7) with a score >2].
  25. Subjects likely to require prohibited concomitant therapy during the trial (see Section 8.6.1).
  26. Subjects who require current use of agents that are strong inhibitors (e.g. quinidine) and inducers (e.g. carbamazepine, phenytoin, rifampin, and phenobarbital) of cytochrome P450 2D6.
  27. Subjects who have received any agent in a clinical trial within 30 days prior to screening; for investigational drugs with an elimination half-life greater than 15 days, this time period will be extended to 60 days.
  28. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness, or who have ongoing legal issues that could affect their ability to continue to participate in this trial.
  29. Subjects who have been hospitalized, including hospitalization for psychosocial reasons, for more than 30 days total in the last 60 days prior to entry into the Screening Phase.
  30. Electroconvulsive therapy within 180 days prior to entry into the Screening Phase.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    2x360 mg risperidone implant

    2, 360 mg risperidone implants

    Drug: Risperidone implant

  • Experimental
    3x300 mg risperidone implant

    3, 300 mg risperidone implants

    Drug: Risperidone implant

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events as Assessed

    The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of Psychotic Symptom Exacerbation/Impending Relapse

    The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.

    Time frame: 12 months

Other outcomes

  1. Change of Sleep Quality From Baseline to Month 12 Measured on the Pittsburgh Sleep Quality Index (PSQI)

    The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.

    Time frame: Baseline and 12 months

07

Results

Posted Feb 19, 2020
Limitations and caveats
The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.

Participant flow

Participant flow — Overall Study
Milestone2x360 mg Risperidone Implant3x300 mg Risperidone Implant
Started00
Completed00
Not completed00

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events as Assessed

The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.

Time frame:
12 months

No measurements were reported for this outcome.

SecondaryIncidence of Psychotic Symptom Exacerbation/Impending Relapse

The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.

Time frame:
12 months

No measurements were reported for this outcome.

Other pre-specifiedChange of Sleep Quality From Baseline to Month 12 Measured on the Pittsburgh Sleep Quality Index (PSQI)

The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.

Time frame:
Baseline and 12 months

No measurements were reported for this outcome.

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2x360 mg Risperidone Implant———
3x300 mg Risperidone Implant———

Baseline characteristics

The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.

Age, Categorical
Age, Categorical2x360 mg Risperidone Implant3x300 mg Risperidone ImplantTotal
<=18 years———
Between 18 and 65 years———
>=65 years———
Age, Continuous
Age, Continuous2x360 mg Risperidone Implant3x300 mg Risperidone ImplantTotal
Sex: Female, Male
Sex: Female, Male2x360 mg Risperidone Implant3x300 mg Risperidone ImplantTotal
Female———
Male———
Race (NIH/OMB)
Race (NIH/OMB)2x360 mg Risperidone Implant3x300 mg Risperidone ImplantTotal
American Indian or Alaska Native———
Asian———
Native Hawaiian or Other Pacific Islander———
Black or African American———
White———
More than one race———
Unknown or Not Reported———
Region of Enrollment
Region of Enrollment(participants)2x360 mg Risperidone Implant3x300 mg Risperidone ImplantTotal
08

Study locations

1 site
  • Collaborative Neuroscience Network
    Garden Grove, California 92845, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Sep 2017, 17 months.

Results were first posted in Feb 2020, 2 years 5 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 17 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2016
First posted
May 16, 2016
StartActual
Apr 2016
Primary completionActual
Sep 2017
CompletionActual
Sep 2017
Results first posted
Feb 19, 2020
Last update
Feb 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02773576
Lead sponsor
Braeburn Pharmaceuticals
Responsible party
Sponsor
First posted
May 16, 2016
Start date
Apr 2016
Primary completion
Sep 2017
Completion
Sep 2017
Results posted
Feb 19, 2020
Last update
Feb 19, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion